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Abstract RNA interference (RNAi) is an important avenue
for target-specific gene silencing that is mainly performed by
either small interfering RNAs (siRNAs) or microRNAs
(miRNAs). This novel method is rapidly becoming a powerful
tool for gene therapy. However, the rapid degradation of
siRNAs and miRNAs and the limited duration of their action
in vivo call for an efficient delivery technology. Recently,
increasing attention has been paid to the use of extracellular
vesicles (EVs) as delivery systems. The use of EVs as small
RNA carriers has multiple advantages over conventional de-
livery systems. In this review, we summarize recent findings
regarding the potential application of EVs as small RNA
delivery systems. Moreover, we focus on some of the obsta-
cles to EV-based therapeutics.
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Introduction
Therapeutic strategies are essential for curing human diseases
[1]. Therefore, a continuous search for new approaches to
tackle human diseases is important. The discovery of RNAi,
which is mainly performed by either small interfering RNAs
(siRNAs) that degrade mRNA or microRNAs (miRNAs) that
attenuate translation, for target-specific gene silencing has
rapidly created a powerful tool for the exploration of patho-
genesis of human disease [2–4]. The identification of these
remarkable molecular pathways has manifested a new field of
gene therapy. However, the clinical use of miRNA or siRNA
entails at least two critical steps: delivery of miRNA or siRNA
to the appropriate tissues and subsequent maintenance and
expression. A key goal of target-specific RNAi delivery tech-
nology for several diseases is the development of delivery
systems directed at the target tissues only. Currently, there are
many types of drug delivery systems. However, these methods
have several limitations such as the lack of delivery systems
that are safe, efficient, tissue specific and that do not cause
immune and inflammatory responses when they are used
in vivo.
It has been well known for decades that miRNAs can be
detected in human body fluids such as plasma, saliva, and
breast milk, although ribonucleases circulate throughout the
body [5–9]. This finding suggested that miRNAs are inserted
into RNase-resistant lipid vesicles before secretion. Indeed, it
has been reported that miRNAs exist in extracellular vesicles
such as exosomes and microvesicles [10]. Exosomes and
microvesicles are produced by many cell types such as cancer
cells [11], dendritic cells [12], intestinal epithelial cells [13], T
cells [14], and B cells [15]. One current definition is that
exosomes are small membrane vesicles (40–100 nm) from
multivesicular endosomes, whereas microvesicles (50–1,
000 nm) are generated by budding at the plasma membrane
[16]. However, no current consensus exists on the precise
definition of exosomes and microvesicles. Therefore, we used
“extracellular vesicles (EVs)” as all types of vesicles in the
extracellular space throughout the paper as recommended by
the “International Society for Extracellular Vesicles,”which is
the international exosomes and microvesicles community.
Trams et al. initially reported in 1981 that exfoliated mem-
brane vesicles with 5′-nucleotidase activity can detect from
various normal and neoplastic cell lines (Table 1) [17].
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Moreover, Pan et al. demonstrated the existence of 50-nm
membrane vesicles secreted from sheep reticulocytes using
electron microscopy [18]. Since then, EVs have been consid-
ered as waste disposal agents for cells because EVs are similar
to apoptotic blebs. However, apoptotic blebs are rapidly
cleared in circulation by phagocytosis due to phospha-
tidylserine exposure [19]. In addition, EVs became of interest
for immunologists in the 1990s. Raposo et al. showed that
EVs derived from both human and murine B lymphocytes
activated T cell immune responses [15]. Most importantly,
Valadi et al. demonstrated that EVs derived from various cell
types contain RNA including mRNA and miRNA in 2007
[10]. In addition, three groups independently discovered that
EVs contain miRNA transferred between cells and subse-
quently suppress the target genes in recipient cells [20–22].
They demonstrated that miRNAs traveled between cells using
EVs, and these RNAs are functional in transmitted recipient
cells [20–22]. In particular, Pegtel et al. demonstrated that total
RNAs from 2×104 cells of monocyte-derived dendritic cells
(MoDC) co-cultured with EBV-transformed lymphoblastoid
B cells (LCL) contained over thousands of individual EBV-
miRNA copies as little as 500 pg of exosomal RNA fromLCL
cells [20]. This finding indicates that 500 pg of EVs was
physiologically relevant because at least 100 miRNA copies
could suppress target mRNAs in mammalian cells [23]. These
reports raised the idea that EVs are small RNA carriers and
can be used as a source of effective delivery strategies. There
are many reports showing the concept of using EVs for RNA
delivery based on the discovery of miRNA transfer (Table 2).
In this article, we review the latest reports regarding EVs and
the potential for small RNA delivery using EVs. The rele-
vance of EVs and their therapeutic uses are then considered.
Small RNA delivery with EVs
As shown above, miRNA can be delivered by EVs. Currently,
it is well known that miRNA profiling is a valuable diagnostic
and prognostic tool for characterizing a wide range of pathol-
ogies [24]. Similarly, targeting aberrantly expressed miRNAs
offers new therapeutic possibilities [25]. For instance, we
demonstrated that injection of miR-16 in tumor-bearing mice
suppressed prostate tumor growth by regulating the expres-
sion of genes associated with cell cycle control and cellular
proliferation such as CDK1 and CDK [26]. In addition, Kota
et al. demonstrated that systemic administration of miR-26a in
hepatocellular carcinoma-bearing mice using adeno-
associated virus suppressed tumor growth without toxicity
by downregulating cyclins D2 and E2 [4]. Although many
reports show the potential of miRNA for therapeutic purposes,
it is quite difficult to decide which types of delivery methods
are most appropriate for miRNA because of the limitation in
conventional methods such as stability and immunogenicity.
Thus, EVs have considerable promise as new delivery sys-
tems. There are many reports demonstrating EVs as therapeu-
tic miRNA carriers. We previously demonstrated that the
culture supernatant of normal epithelial prostate cells inhibited
proliferation of prostate cancer cells in vitro and in vivo [27].
In particular, miR-143, which is a tumor-suppressive miRNA,
could induce growth inhibition through downregulation of
KRAS and ERK5 expression in prostate cancer cells. Inter-
estingly, the surface of EVs can be modified by the genetic
engineering of donor cells for efficient delivery of EVs to
target cells. Ohno et al. generated modified EVs derived from
Table 1 Historical key developments in studies of the EVs after 1980s
Year Milestone discovery References
1981 EVs were reported [17]
1985 EVs were detected by electron microscopy [18]
1996 EVs presenting immune antigen were discovered [15]
1998 RNAi was discovered [3]
2007 Valadi et al. first reported that EVs contain mRNA
and miRNA
[10]
2010 Three groups confirmed that miRNAs in EVs
functionally transfer between cells
[20–22]
2011 Delivery of siRNA by EVs in vivo was demonstrated [29]
Table 2 List of successful small RNA deliveries by EVs in both basic and clinical research
Small RNA Target gene Donor cells Recipient cells or tissue Small RNA loading methods References
miR-143 KRAS Human normal prostate cell line Human prostate cancer cell line Stable cell lines over-expressing
of miRNA by expressing vector
[27]
ERK5
let-7a Human embryonic kidney cell lines Human breast cancer cell lines Lipofection of synthetic miRNA
to donor cells
[28]
siRNA GAPDH Murine dendritic cells Neurons, microglia, oligodendrocytes Electroporation [29]
BACE1 Murine dendritic cells Cortical tissue Electroporation
siRNA HCV Human hepatoma cell lines Human hepatoma cell lines Stable cell lines over-expressing
of shRNA by expressing vector
[30]
CD81 Human B lymphocytes Mouse liver cells
siRNA MAPK1 Human peripheral blood cells Human T cells, monocyte Electroporation [31]
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the human embryonic kidney cell line HEK293with the GE11
peptide, which specifically binds to epidermal growth factor
receptor (EGFR), or EGF, on their surfaces. These modified
EVs can efficiently deliver let-7a miRNA to EGFR-
expressing xenografted breast cancer tissue in immunodefi-
cient mice [28]. These observations suggested that EVs can be
used for miRNA replacement therapy by restoring the expres-
sion of miRNA, which is downregulated in target cells. Con-
versely, siRNA has been shown to have more specific inhibi-
tion compared to miRNA because miRNAs generally have the
ability to bind many target mRNAs. Our groups previously
reported that not only cellular miRNA but also exogenous
siRNA, which is artificial small RNA, can be transported into
recipient cells using EVs. This finding suggested that the
loading mechanisms of siRNA into EVs are similar to miRNA
[22]. Based on these findings, Alvarez-Erviti et al. generated
EVs derived from murine immature dendritic cells expressing
the membrane protein Lamp2 fused to the neuron-specific
rabies viral glycoprotein peptide. Therefore, modified EVs
are used as delivery tools into the mouse brain [29]. Interest-
ingly, siRNA against GAPDH can be delivered specifically to
neuron microglia and oligodendrocytes in the mouse brain via
EVs. Moreover, nonspecific uptake in other tissues was not
observed. Furthermore, C57BL/6 normal mice were injected
intravenously with siRNA encapsulated in EVs targeting
BACE1, which is a strong candidate for anti-Alzheimer′s
disease. The strong mRNA (60 %) and protein (62 %) knock-
down of BACE1 was observed in cortical tissue. Pan et al.
showed that transmission of siRNA targeting HCVor CD81
was partially mediated by EVs in both human and mouse liver
cells in vitro [30]. More importantly, siRNA transmission
in vivo was confirmed using immunodeficient mice engrafted
with human hepatoma cells producing CD81 siRNA, and
consequently, suppression of CD81 expression in mouse he-
patocytes was observed. Additionally, Wahlgren et al. showed
that MAPK1 siRNAwas loaded into the EVs derived from the
peripheral blood of healthy donors by electroporation. Then,
they confirmed that MAPK1 siRNA in EVs were transferred
to human blood cells such as T cells and monocytes [31].
Taken together, these reports suggest that EVs are a promising
application of small RNA delivery. However, further investi-
gation is needed because we are still at an early stage of
investigation regarding the nature of EVs.
Potential of EVs to overcome the flaws of conventional
delivery systems
It is conceivable that using EVs as delivery systems has some
advantages over conventional carrier systems. First, the contents
of EVs can be modified with genetic engineering of the parent
cells for efficient delivery of EVs to target cells if required. Kim
et al. reported that EVs derived from genetically modified bone
marrow-derived dendritic cells expressing FasL, which induces
significant antiarthritic effects in mouse, can inhibit inflamma-
tion in a murine footpad model of delayed-type hypersensitivity
[32]. Secondly, EVs compensate for the shortcomings of con-
ventional drug delivery systems. Adeno-associated virus (AAV)
vector is a promising gene delivery vector [33]. However, AAV
tends to transduce into liver cells after intravenous delivery,
reducing its usefulness for targeted sites [34]. Maguire et al.
found that the AAV capsid existed not only as a free particle but
also inside EVs, which are termed as “vectosomes,” in culture
medium after transfection of AAV into 293T cell lines [35].
Furthermore, vectosomes could enhance the gene transfer in
human glioblastoma cell lines compared to conventionally pu-
rified AAV vectors. Additionally, vectosomes with magnetic
beads can be attracted to a magnetized area in human glioblas-
toma culture cells. These findings suggest that the use of a
combination of conventional delivery systems and EVs can be
a powerful tool for therapy. Sun et al. demonstrated that the
formation of EV–curcumin complexes leads to an increase in
the stability of curcumin in vitro and in bioavailability in vivo
compared to curcumin only. It is quite interesting to find new
therapeutic methods, such as combinations of conventional
delivery systems and EVs, for improved therapies.
Critical points that need to be solved in EV-based
therapeutics
Although EVs constitute a novel application for small RNA
delivery, some features of EV biology remain unclear.
Stability of EVs
It is well known that naked siRNA is generally difficult to
deliver primarily due to the rapid clearance and the limited
serum half-life of 5–60 min of unmodified siRNA [36, 37]. It
has been suggested that EVs are relatively stable in the blood
because extracellular miRNAs stably exist in human body fluid
[6]. In fact, Chen et al. demonstrated that miRNAs in normal
human serum under harsh conditions including ten freeze–thaw
cycles, low (pH=1) or high (pH=13) pH solution treatment,
and DNase treatment yield no significant differences compared
to nontreated serum samples [38]. Moreover, Koga et al. re-
ported that miRNAs in EVs were conserved under RNase
(5 μg/ml) treatment for 30 min, whereas naked miRNAs were
degraded within 30 min [39]. However, there is one evidence
that murine melanoma-derived EVs are rapidly cleared from
the blood circulation with a half-life of approximately 2 min
after systemic administration [40]. Therefore, it is essential to
know the half-life of EVs in the bloodstream so that the
measurement of sequential plasma concentrations of EVs after
administration can be used to establish dosage regimens that are
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likely to produce the desired therapeutic levels for appropriate
periods of time without the risk of toxicity in EVs.
Components of EVs
It is important to identify endogenous miRNAs in EVs, which
could result in side effects, because EVs contain many kinds
of miRNAs [20]. In fact, we previously demonstrated that
exosomal miR-210 from metastatic cancer cells could lead
the microenvironment of endothelial cells to the benefit of
cancer cells promoting cancer metastasis [41]. Moreover, the
expression profiles of miRNAs in EVs obtained from meta-
static cancer cells demonstrated that a set of angiogenic
miRNAs was highly concentrated compared to normal cells.
On the other hand, as shown above, our groups reported that
supernatant from normal cells inhibited the proliferation of
cancer cells [27]. In particular, miR-143 in culture supernatant
can induce inhibition of cancer cell growth. From these ob-
servations, we propose that enrichment of tumor-suppressive
miRNAs can ignore the effects of cancer-promoting miRNAs
in EVs. For this reason, knowing the expression profile of
miRNAs in EVs is essential. It is also essential that the protein
content in EVs be determined by proteomic analysis to iden-
tify any endogenous proteins that may mediate potential
unwanted side effects. ExoCarta, which is an EV database
(http://exocarta.org), provides the exosomal contents that
were identified in some organisms. Most exosomal proteins
identified thus far are conserved between cell types [42]. In
particular, the tetraspanin family including CD9, CD63,
CD81, and CD82 has been found in EVs derived from many
cell types. However, proteomic analysis by many researchers
has proven that the protein content of EVs may vary
depending on the host cells. For instance, Blanchard et al.
demonstrated that EVs derived from human Tcells upon TCR
stimulation contain CD3 as a specific marker [14]. If these
types of EVs are used for therapeutic purposes, this could
induce unwanted immune activation. On the other hand, EVs
may contain high amounts of proteins with tumor suppressor
properties. In fact, Putz et al. demonstrated that PTEN protein,
a tumor suppressor protein, was secreted in EVs, and secreted
PTEN was functionally transferred to recipient cells, resulting
in the inhibition of cell proliferation through reduction of Akt
phosphorylation [43]. These findings indicate that EVs can
package specific proteins, which are downregulated in disease
and may be used as therapeutic delivery tools. Although the
functions of most proteins in EVs are still unknown, further
proteomic analysis is important for preventing the harmful
side effects of EVs as therapeutic tools.
Purification methods of EVs
To use EVs as delivery systems for therapy, it is very impor-
tant to examine the purity of EVs because non-exosomal
proteins induce unwanted immune responses. Rood et al.
demonstrated that proteins may also contaminate isolated
EVs after ultracentrifugation or nanomembrane ultrafiltration
preparations from human urine samples [44]. Moreover,
Gyorgy et al. reported that preparation of EVs isolated by
ultracentrifugation can detect contaminants such as immune
complex proteins [45]. Electroporation of EVs with siRNA is
accompanied by extensive siRNA aggregation and non-
capsulated siRNA from EV surface that cannot be removed
before mouse in vivo experiments [46]. Therefore, purifica-
tion methods such as sucrose cushion, sucrose-iodixanol gra-
dients, or RNase treatment are essential before mouse injec-
tion to exclude excess siRNA [47]. In general, EVs are isolat-
ed by ultracentrifugation although the yield of EVs is quite
low. However, large amounts of EVs are required if EVs are to
be used as a therapy resource. Indeed,Mitchell et al. reported a
novel culture system by using the CELLine Adhere 1000
(CLAD1000) flask to obtain a high amount of EVs from
adherent and nonadherent tumor cells compared to conven-
tional methods [48]. Development of useful and easy methods
for significant increasing quantity of EVs is important for
usage of EVs as drug delivery cargo. Taken together, it is
essential to develop novel isolation methods instead of
patient
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Fig. 1 Schematic representation of the paradigm shift in EVs. Since their
discovery, EVs were initially considered to solely be cellular waste
elimination systems (a). However, EVs have recently been found to
contain both mRNA and miRNA. Additionally, EVs can be transferred
between cells, and exosomal miRNAs were functional in recipient cells
(b). Therefore, many researchers hope that EVs can be used as novel
RNAi delivery systems for human therapy in the near future (c)
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ultracentrifugation to prevent potentially harmful immune
responses and to increase the yield of EVs.
Internalization of EVs
To avoid unwanted delivery, therapeutic EVapplication requires
knowledge of EV uptake mechanisms. There are two possible
mechanisms of EV uptake: endocytosis and fusion [49]. How-
ever, whether EVs enter cells via endocytosis or fusion remains
controversial. Barres et al. demonstrated that uptake of rat
reticulocyte EVs by macrophages decreases upon adding
galectin-5 [50]. This finding suggests that galectin-5 associates
with EVuptake through the endocytic pathway. Moreover, Tian
et al. used live-cell microscopy to show that EVs derived from
rat pheochromocytomas were internalized by resting rat cells
through the endocytosis pathway [51]. Feng et al. reported that
EVs from K562 human erythroleukemia or MT4 HTLV-
transformed T cell leukemia are taken up more efficiently by
phagocytic cells than non-phagocytic cells because macrophage
cells expressed TIM-4, which is one of the receptors to phago-
cytose EVs [52]. Moreover, dynamin2, which is an important
regulator of phagolysosomes, is required for EV uptake. In
addition, Svensson et al. found that uptake of EVs from glio-
blastoma cells was negatively regulated by the lipid raft-
associated protein caveolin-1 through regulation of the ERK1/
2 signaling pathway [53]. Conversely, Parolini et al. reported
that EVs derived from melanoma cells enter melanoma cells
through membrane fusion [54]. Further investigation is needed
to explain the discrepancies observed in different studies.
Induction of immune response by EVs
It is essential to investigate whether host-derived EVs induce an
immune response with subsequent side effects. Interestingly,
there are some evidences that viruses exploit the EV biogenesis
pathway for disease spreading. Indeed, Feng et al. reported that
the hepatitis Avirus uses the host-derivedmembrane resembling
EVs, protecting the virus particles from antibody neutralization
and promoting virus spread within the liver [55]. These findings
support that host-derived EVs may escape from the immune
response. In addition, Narayanan et al. demonstrated that HIV-1-
infected cells produced EVs containing trans-activation re-
sponse element (TAR) RNA, which is viral miRNAs. They also
showed that TAR RNA in EVs inhibited apoptosis by down-
regulation of Bim, which is a pro-apoptotic protein, in recipient
cells [56]. However, there is some evidence regarding patient-
derived EV-induced immune response. Alvarez-Erviti et al. re-
ported that both siRNAwith EVs or in vivo transfection reagents
induce a low immune response in vivo [29]. Moreover, Sun
et al. also demonstrated that production levels of IL-6 and
TNF-α in the supernatant after stimulation with LPS display
no difference between EVs and PBS [57]. In general, induced
pluripotent stem cells (iPSCs) cause no immune response
because iPSCs are generated from patient cells [58]. However,
Zhao et al. reported that the transplantation of immature iPSCs
induced a Tcell-dependent immune response even in a syngenic
mouse [59]. These findings suggested that patient-derived cells
have the potential for abnormal gene expression under culture
conditions. Therefore, the immunogenicity of therapeutically
valuable EVs derived from patient cells should be examined
before the initiation of EV clinical applications. Taken together,
further studies will be needed to characterize EVs for RNAi
therapeutic applications further, and better knowledge of EVs
may solve these problems.
Conclusion
Since EVs were first discovered over 30 years ago, the char-
acterization of their cellular origin and function has been
gradually revealed. In particular, the discovery of EVs as
natural carriers of miRNA led to the possibility that they can
be used as vehicles for the delivery of exogenous therapeutic
cargoes. In this review, we summarize the most recent findings
regarding EVs for small RNA delivery. Although there are
growing concerns about EV small RNA delivery potential,
there also exist some limiting factors in clinical translation.
However, EVs have some advantages for use as a therapeutic
application for small RNA delivery compared to conventional
therapy if several issues are resolved (Fig. 1). In conclusion, it
is highly likely that EVs will be the application used for novel
RNAi delivery systems for human therapy in the near future.
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